| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.097 | 0.004 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.005 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.099 | 0.005 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.092 | 0.008 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.01 |